BioSight
Companies
Corbus Pharmaceuticals Holdings, Inc. logo

CRBP

NASDAQNORWOOD, MA
Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals is a clinical-stage biotech company developing two drugs: CRB-701, an antibody-drug conjugate targeting Nectin-4 on cancer cells for oncology indications including cervical cancer and head and neck squamous cell carcinoma, and CRB-913, a cannabinoid receptor antagonist for obesity treatment. CRB-701 is currently in Phase 1/2 trials in the Western markets and has received FDA fast-track designation, while CRB-913's development stage is not detailed in this excerpt.

Price history not yet available for CRBP.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar